Submitted by endpointsnews6292 in business
Bristol Myers Squibb cited lower Revlimid sales as a driver of its falling revenue in
Submitted by endpointsnews6292 in business
Bristol Myers Squibb cited lower Revlimid sales as a driver of its falling revenue in
Submitted by endpointsnews6292 in business
Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option
Submitted by endpointsnews6292 in health
Most HIV patients in a Phase III study investigating ViiV Healthcare's long-acting injectable
Submitted by endpointsnews6292 in business
Illumina must pay a €432 million ($476 million) fine for buying the cancer-testing firm
Submitted by endpointsnews6292 in business
The end of EQRx has officially arrived. EQRx will be acquired by Revolution Medicines in
Submitted by endpointsnews6292 in business
Dutch biotech argenx launched a $750 million offering the same day it shared promising data
Submitted by endpointsnews6292 in business
Certain patients with type 1 diabetes now have an option to use cell therapy thanks
Submitted by endpointsnews6292 in business
AbbVie largely beat expectations in its second-quarter earnings update, and execs were quick to
Submitted by endpointsnews6292 in business
Peter Marks, the senior FDA official who oversees the regulation of gene therapies, overrode agency
Submitted by endpointsnews6292 in business
AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies
Submitted by endpointsnews6292 in business
Regeneron said late Tuesday that the FDA rejected its new, 8-mg version of its
Submitted by endpointsnews6292 in business
Sanofi was the mystery “Party A” that engaged in a bidding war with Biogen for
Submitted by endpointsnews6292 in business
The FDA approved Regeneron’s pozelimab, the first treatment for a rare, hereditary immune disease
Submitted by endpointsnews6292 in business
Moderna said that preliminary data in humans on its updated Covid-19 vaccine suggest it
Submitted by endpointsnews6292 in business
CARsgen will test its Claudin18.2 CAR T-cell candidate, dubbed CT041, in combination with Moderna
Submitted by endpointsnews6292 in business
Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200
Submitted by endpointsnews6292 in business
The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia
Submitted by endpointsnews6292 in business
Johnson & Johnson’s Janssen plans to close down its vaccine and infectious disease unit in
Submitted by endpointsnews6292 in health
Pfizer said it expects fewer people will be needed to complete its Phase III trial
Submitted by endpointsnews6292 in business
On a quest not just to catch up with, but leapfrog, Amgen and Mirati in
Submitted by endpointsnews6292 in business
AstraZeneca’s rare disease asset Ultomiris was presented with a CRL for neuromyelitis optica spectrum
Submitted by endpointsnews6292 in business
Two biotech companies, Neumora and RayzeBio, hashed out their IPO plans Monday morning, detailing hopes
Submitted by endpointsnews6292 in business
Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease
Submitted by endpointsnews6292 in health
Scientists at MIT have revamped mRNA Covid jabs to boost their immune responses, potentially paving
Submitted by endpointsnews6292 in business
Moderna has inked a deal worth up to $1.8 billion with TCR specialist Immatics that
Submitted by endpointsnews6292 in business
Madrigal Pharmaceuticals has appointed ex-Sanofi executive Bill Sibold as its new CEO, succeeding Paul
Submitted by endpointsnews6292 in business
Preliminary mid-stage data from two rival TROP2-targeting ADCs advanced by AstraZeneca/Daiichi Sankyo and
Submitted by endpointsnews6292 in business
Rocket Pharmaceuticals announced Wednesday that it expects to raise $175 million from a stock sale
Submitted by endpointsnews6292 in business
The FDA's Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 9-3 in
Submitted by endpointsnews6292 in business
Flagship Pioneering’s AI-focused startup Generate:Biomedicines has raised another megaround that will push
Submitted by endpointsnews6292 in business
Moderna is beefing up its pipeline over the next five years with a plan launch
Submitted by endpointsnews6292 in business
Lonza CEO Pierre-Alain Ruffieux is set to leave the Swiss contract manufacturer at the
Submitted by endpointsnews6292 in business
BridgeBio will gain about $250 million via a private investment as the biotech nears an
Submitted by endpointsnews6292 in business
In its second deal announced Wednesday morning, Roche’s Genentech is signing up with Orionis
Submitted by endpointsnews6292 in business
Travere Therapeutics’ kidney disease drug narrowly failed its confirmatory study seven months after it won
Submitted by endpointsnews6292 in business
I2o Therapeutics CEO Kurt Graves set out on Thursday to make a case to a
Submitted by endpointsnews6292 in business
Taysha Gene Therapies discontinued development of a neurodegenerative therapy after the FDA again insisted on
Submitted by endpointsnews6292 in health
One of the backbones of cancer medicine is shutting down key cancer-driving pathways to
Submitted by endpointsnews6292 in business
Novo Nordisk will broaden its cardiometabolic pipeline by pairing up with machine learning and drug
Submitted by endpointsnews6292 in business
Omega Therapeutics, a company designing genetic medicines that dial the output of genes up or
Submitted by endpointsnews6292 in business
In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new
Submitted by endpointsnews6292 in business
As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug
Submitted by endpointsnews6292 in health
The FDA approved a Houston drugmaker’s tablet for adults with major depressive disorder last
Submitted by endpointsnews6292 in business
A massive research collaboration between 13 pharmaceutical companies and the UK Biobank has uncovered a
Submitted by endpointsnews6292 in business
The FDA on Friday unveiled new details around a rare disease pilot program that seeks
Submitted by endpointsnews6292 in business
Providence, a massive health system based in the Seattle area with 51 hospitals, is launching
Submitted by endpointsnews6292 in business
Novartis said that its experimental complement inhibitor iptacopan reduced the buildup of protein in the
Submitted by endpointsnews6292 in business
All companies with drugs on CMS' list for the first round of Medicare price negotiations
Submitted by endpointsnews6292 in business
Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is
Submitted by endpointsnews6292 in health
Stanford scientists have hatched a new type of drug that can turn a cancer promoter